These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 597473)

  • 1. Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.
    Thatcher N; Palmer MK; Gasiunas N; Crowther D
    Br J Cancer; 1977 Dec; 36(6):751-62. PubMed ID: 597473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocyte function related to survival curves in patients with metastatic melanoma treated by chemoimmunotherapy.
    Thatcher N; Palmer MK; Swindell R; Crowther D
    Med Pediatr Oncol; 1978; 4(1):59-70. PubMed ID: 625264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Feb; 35(2):171-9. PubMed ID: 312169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients.
    Thatcher N; Crowther D
    Dev Biol Stand; 1977 Apr 13-15; 38():449-53. PubMed ID: 608536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly sequential study of melanoma patients. I. Changes in non-specific (NK, K and T cell) lymphocytotoxicity, peripheral blood counts and delayed hypersensitivity reactions.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 May; 36(2):227-36. PubMed ID: 314367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly study of melanoma patients II. Changes in serum immunoglobulins and lymphoid cell subpopulations.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Jun; 36(3):456-64. PubMed ID: 487647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
    Lieberman R; Wybran J; Epstein W
    Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoimmunotherapy increases the lymphocyte reactivity of melanoma patients.
    Berkelhammer J; Mastrangelo MJ; Bellet RE; Berd D; Prehn RT
    Eur J Cancer (1965); 1979 Feb; 15(2):197-204. PubMed ID: 436896
    [No Abstract]   [Full Text] [Related]  

  • 9. Thymostimulin therapy in melanoma patients: correlation of immunologic effects with clinical course.
    Bernengo MG; Fra P; Lisa F; Meregalli M; Zina G
    Clin Immunol Immunopathol; 1983 Sep; 28(3):311-24. PubMed ID: 6603936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in the rosette forming capacity of lymphocytes after surgery or surgery and immunochemotherapy of malignant melanoma in man.
    Hadjikirova M; Boeva M; Ikonopisov R
    Biomed Pharmacother; 1982; 36(5):257-9. PubMed ID: 7168802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
    Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
    Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
    Kokoschka EM; Cerni C; Micksche M
    Oncology; 1977; 34(5):229-33. PubMed ID: 917456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 Jan; 35(1):36-44. PubMed ID: 428146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant melanoma (stage IIIB): a pilot study of adjuvant chemo-immunotherapy.
    Paterson AH; McPherson TA; Willans DJ
    Cancer Treat Rep; 1978 Apr; 62(4):571-3. PubMed ID: 350395
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunological status may predict clinical outcome in BCG treated melanoma.
    Reynolds PM; Grimsley G; Dawkins RL; Byrne MJ; Zilko PJ
    Aust N Z J Med; 1980 Feb; 10(1):39-43. PubMed ID: 6966494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged BCG treatment of melanoma: does it suppress the immune capacity?
    Helander I; Nordman E; Häkkinen IP; Toivanen A
    Br J Dermatol; 1979 Oct; 101(4):421-7. PubMed ID: 508607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCG immunotherapy in previously treated malignant melanoma patients.
    Mujagić H; Kolarić K; Malenica B; Nola P
    Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of bacillus Calmette-Guerin immunotherapy on tumor antigen-induced lymphocyte-stimulated protein synthesis in melanoma patients.
    Roth JA; Golub SH; Holmes EC; Morton DL
    Surgery; 1975 Jul; 78(1):66-75. PubMed ID: 1138401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current concepts in the management of malignant melanoma.
    Lichtenfeld JL
    Am J Med Sci; 1976; 272(2):185-95. PubMed ID: 1008080
    [No Abstract]   [Full Text] [Related]  

  • 20. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.